Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since. Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

Hexa Chemical Co., Ltd. engages in the manufacturing and sale of plastic colorants, colored and functional master batches and applied products. The company was founded on May 4, 1970 and is headquartered in Osaka, Japan.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Lanzhou Xinlongtai Biotechnology Co., Ltd., established on 2019-06-27, The business scope includes chemical raw materials,Pesticides and Pesticide Intermediates(Free of Hazardous Chemicals)research and development,production and sales(Matters subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Anhui Delongtai Chemical Co., Ltd., established on 2008-03-14, Business scope includes general items:Chemical product production(No licensed chemical products);Import and export(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Hebei Veyong Bio-Chemical Co. Ltd. manufactures and distributes veterinary pharmaceuticals. The firm’s offerings include technical, products under developing, formulated, and mixture formulated products. The company is headquartered in Shijiazhuang, China.

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver mutations,” in contrast to those merely along for the ride as “passenger mutations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific genetic vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allows us to construct drugs with best-in-class properties from the ground up.

Jiangsu Anpon Electrochemical Co., Ltd. engages in the production and sale of chemical raw materials and chemical products. Its business activities include wholesale of chemical products, underground rock salt mining, production and sale of pesticides, welding gas cylinder inspection, generation of steam and waste heat power, manufacture and sale of packaged goods, and carbon label printing. The company was founded on November 25, 1998 and is headquartered in Huaian, China.

Involved in the production of photographic equipment.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Ningbo Shentai Biotechnology Co., Ltd., established on 2017-11-01, Business scope includes biotechnology,Technology development in the field of medical technology,technology transfer,Technical Consulting and Technical Services;Biological product,Research and development of plant extracts;Pharmaceutical Intermediates(Removal of hazardous chemicals,precursor chemicals,medicine),Chemical Products(Removal of hazardous chemicals and precursor chemicals),Research and development of food additives,Sales;Wholesale of experimental analysis instruments and consumables,retail;food research and development,operate;Disinfection supplies,R&D of cosmetics,wholesale,retail;Import and export of self-operated and agent goods and technologies,Except for goods and technologies that are restricted by the state or prohibited from import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kaili Catalyst & New Materials Co., Ltd. engages in the research and development and production of precious metal catalysts. It specializes in research and development of catalytic application technology, and recovery and reprocessing of waste precious metal catalysts. Its products include palladium series of catalysts, platinum series catalyst, rhodium series catalysts, ruthenium series catalyst, and iridium series catalyst. Its products and services are used in medicine, new chemical materials, pesticides, dyes and pigments, environmental protection, new energy, electronics, and basic chemicals. The company was founded on March 15, 2002 and is headquartered in Xi'an, China.

Nanyang Junhao Chemical Co., Ltd., established on 2018-06-06, Business scope includes sales of chemical products(Excluding flammable, explosive and highly toxic items);Manufacture of triazineamide from organic chemical raw materials,Niacinaldehyde,pyrazole ether,PAC,ammonium chloride,Sodium chloride,right(adjacent,between)Fluorobenzaldehyde,right(adjacent,between)Fluorobenzoic acid,right(adjacent,between)Fluorobenzoyl chloride,right(adjacent,between)Fluorochlorobenzyl,right(adjacent,between)Methyl fluorobenzoate,right(adjacent,between)ethyl fluorobenzoate,glassware,sanitary material,Analytical Instruments(Does not contain medical devices),chemical reagent(Flammable and explosive,Easy to poison,Excluding chemical hazards)Production and sales;import and export trade;Online Trade Agent*Involved in licensing projects,It should be operated after obtaining the permission of the relevant department